Science Corporation has recently acquired the IP and related assets of the Pixium Vision Prima implant, a groundbreaking technology that offers a potential solution for individuals suffering from blindness. The Prima System, which acts as a photovoltaic substitute for photoreceptors, has already received FDA breakthrough device designation and provides simultaneous use of central prosthetic and peripheral natural vision. It was specifically designed for patients with atrophic dry age-related macular degeneration (AMD), offering a miniaturized, wireless, subretinal implant paired with a pocket computer and glasses.
The acquisition of the Prima System adds to Science’s already impressive IP portfolio and represents a significant step forward in the company’s mission to develop cutting-edge brain-computer interface (BCI) technology. Neuralink co-founder Max Hodak, who founded Science Corporation, expressed excitement about the acquisition and the opportunity it presents for developing BCI technology for vision restoration.
Outgoing Pixium CEO Lloyd Diamond expressed confidence in Science’s ability to continue the development and commercialization of the Prima System, stating that it now has a home with a team dedicated to helping patients. He added that he believes this collaboration will have a positive impact on the field of vision restoration and on the lives of individuals affected by blindness.
Science is now able to provide continuity for patients enrolled in Pixium Vision’s clinical trials, ensuring that they receive further innovative products using different modalities. The acquisition also paves the way for Science to further advance its research in this area, which could lead to new breakthroughs in BCI technology.